Gynecologic Cancer & the Negative Impacts of COVID-19
Among the disruptions in timely medical care caused by the COVID-19 pandemic is the receipt of...
Read More
Dissemination (Meeting Coverage)
Immunotherapy for Advanced Uterine Cancer Is Underutilized
The use of the FDA-approved checkpoint inhibitor pembrolizumab in clinical practice—for previously...
Read More
Uterine Cancer Benefits With Lenvatinib Plus Pembrolizumab Dose Reductions
The toxicity observed with full doses of lenvatinib and the underrepresentation of Black...
Read More
Text Messaging After Gynecologic Cancer Surgery Feasible & Effective
The standard of care following gynecologic oncology surgery may include post-discharge calls to...
Read More
Endometrial Hyperplasia Staging: Avoiding Reoperation With SLN Mapping
To determine whether sentinel lymph node mapping (SLN) in patients with endometrial hyperplasia is...
Read More
Self-Hypnosis Decreases Gynecologic Cancer Surgery Anxiety
With prior research indicating that self-hypnosis (SH) may help reduce preoperative distress and...
Read MoreAlarming Drop in Cancer Screenings Due to Pandemic
A significant drop in the screening, diagnosis and treatment of genitourinary cancers was observed during the early months of the COVID-19 pandemic. Hereafter, a progressive recovery was observed. Notably, the screening rate for...
Read More
Large Phase 3 Trial Tests Novel Combinations for Metastatic ccRCC
An ongoing open-label, randomized phase 3 trial (NCT04736706) will determine the efficacy of the...
Read MoreRucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma
Results from the ATLANTIS trial platform indicate that rucaparib could play a role in the maintenance treatment of metastatic urothelial carcinoma with a DNA repair deficiency that has responded to first-line platinum-based...
Read More
Pembrolizumab Disease-Free Survival Persists Long Term in RCC
Updated data from the KEYNOTE-564 trial shows pembrolizumab disease-free survival persists long...
Read More
Good Response With Nivolumab Plus Axitinib in Metastatic RCC
Combination treatment with nivolumab plus axitinib has achieved a high response rate in...
Read More
Biomarkers Predict Response to Immune Nivolumab (± Ipilimumab) in Advanced RCC
Biomarker analysis of the phase 2 TITAN-RCC trial identified specific immune cell-related...
Read More
Avelumab Plus Axitinib May Benefit High-Risk Early RCC
Results of the NeoAvAx trial indicate that the neoadjuvant combination of avelumab plus axitinib...
Read MoreHealth and Safety at ASCO GU 2022
Individual Accountability ASCO is committed to maintaining the health and safety of all ASCO Genitourinary Cancers Symposium attendees. We will be reviewing the latest Centers for Disease Control and Prevention and World Health...
Read MoreActive Surveillance Helps Delay Systemic Therapy in Some With Metastatic Renal Cell Carcinoma
Active surveillance (AS) may be used effectively in a subgroup of patients(pts) with metastatic renal cell carcinoma (RCC) and indolent disease to postpone the commencement of systemic treatment without affecting long-term...
Read MoreMindfulness App Helps Address Psychosocial Distress in Patients With Metastatic Renal Cell Carcinoma
mRCC was linked to a high incidence of distress, a high degree of symptom load, and a wide range of quality-of-life impairments. A smartphone application aimed at enhancing mindfulness has been developed from a Mindfulness-Based...
Read MoreTele-mentoring Benefits Patients With Renal Cell Carcinoma
In recent years, the overall survival from metastatic renal cell carcinoma (RCC) has improved, mainly in part due to immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). TKI and ICI had distinct and...
Read MoreResponse to Lenvatinib + Pembrolizumab in Advanced Renal Cell Carcinoma Regardless of Biomarker Status
Lenvatinib (lenva) + pembrolizumab (pembro) demonstrated encouraging antitumor activity and controllable safety characteristics in treatment-naive (n=23) or earlier cured metastatic RCC (n=105, initially medicated with immune...
Read MoreASCO GU Program Guide 2022
Thursday, Feb 17: Exhibits Open 10:00 AM – 9:45 PM EST Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond Primary Track: Prostate Cancer 10:45 AM – 12:30 PM EST Optimizing Management of...
Read MoreASCO GU 2022 Is Here!
Program at a Glance • Highly interactive sessions with multidisciplinary perspectives on new, innovative findings in the study, diagnosis, and treatment of GU malignancies. • Presentation of the latest novel science and...
Read More